- Home
- SIGA vs ORGO Comparison
SIGA vs ORGO Comparison
Compare SIGA & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- ORGO
- Stock Information
- Founded
- SIGA 1995
- ORGO 1985
- Country
- SIGA United States
- ORGO United States
- Employees
- SIGA N/A
- ORGO N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- ORGO Health Care
- Exchange
- SIGA Nasdaq
- ORGO Nasdaq
- Market Cap
- SIGA 515.1M
- ORGO 465.6M
- IPO Year
- SIGA 1997
- ORGO N/A
- Fundamental
- Price
- SIGA $9.13
- ORGO $4.89
- Analyst Decision
- SIGA
- ORGO Buy
- Analyst Count
- SIGA 0
- ORGO 2
- Target Price
- SIGA N/A
- ORGO $7.50
- AVG Volume (30 Days)
- SIGA 640.7K
- ORGO 642.5K
- Earning Date
- SIGA 08-05-2025
- ORGO 08-07-2025
- Dividend Yield
- SIGA 6.57%
- ORGO N/A
- EPS Growth
- SIGA N/A
- ORGO N/A
- EPS
- SIGA 1.14
- ORGO N/A
- Revenue
- SIGA $179,639,422.00
- ORGO $429,531,000.00
- Revenue This Year
- SIGA N/A
- ORGO $2.57
- Revenue Next Year
- SIGA $95.31
- ORGO $9.80
- P/E Ratio
- SIGA $8.01
- ORGO N/A
- Revenue Growth
- SIGA 3.86
- ORGO N/A
- 52 Week Low
- SIGA $4.95
- ORGO $2.46
- 52 Week High
- SIGA $9.80
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- SIGA 67.83
- ORGO 59.08
- Support Level
- SIGA $8.39
- ORGO $4.41
- Resistance Level
- SIGA $9.14
- ORGO $4.90
- Average True Range (ATR)
- SIGA 0.50
- ORGO 0.30
- MACD
- SIGA 0.04
- ORGO -0.03
- Stochastic Oscillator
- SIGA 84.19
- ORGO 92.58
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.